Advertisement

Cancer Immunology, Immunotherapy

, Volume 54, Issue 10, pp 999–1009 | Cite as

Complete protection against melanoma in absence of autoimmune depigmentation after rejection of melanoma cells expressing α(1,3)galactosyl epitopes

  • Gabriela R. RossiEmail author
  • Robert C. Unfer
  • Tatiana Seregina
  • Charles J. Link
Original Article

Abstract

The major barrier for xenotransplantation in humans is the presence of α(1–3) Galactosyl epitopes (αGal) in xenogeneic tissue and the vast quantities of natural antibodies (Ab) produced by humans against this epitope. The binding of anti-αGal Ab to cells expressing αGal triggers a complement-mediated hyperacute rejection of target cells. The hyperacute rejection of whole cancer cells, modified to express αGal epitopes, could be exploited as a new cancer vaccine to treat human cancers. We tested this hypothesis in αGalactosyltransferase knockout (αGT KO) mice which, like humans, do not express αGal on their cell surfaces and can produce anti-αGal Ab. Forty-five percent of mice with preexisting anti-αGal Ab rejected αGal positive melanoma cells (B16αGal). These mice remained tumor-free for more than 90 days. The majority of control mice injected with B16Null, αGal negative cells succumbed to melanoma. The rejection of B16αGal induced strong long-lasting antitumor immunity against B16Null measured by the expansion of cytotoxic T lymphocytes. In addition, mice rejecting B16αGal were protected against melanoma since they survived a second rechallenge with B16Null. Protected mice developed antitumor immunity in the absence of autoimmune depigmentation (vitiligo). These results show that rejection of αGal positive melanoma cells can efficiently boost the immune response to other tumor associated antigens present in αGal negative melanoma cells. This study supports the concept of a novel anticancer vaccine to treat human malignancies.

Keywords

Cancer vaccine Alpha(1, 3)Galactosyl epitope Adjuvant Xenotransplant Melanoma 

Notes

Acknowledgments

Rossi GR was funded by NewLink Genetics Corporation through a Research and Development Agreement. The authors would like to thank Dawn Bertrand, for her outstanding efforts and invaluable help in the management of the Animal Care Facility at the Iowa Cancer Research Foundation. The authors also would like to thank Dr Sergei Kisselev for his assistance in the FACS and Dr Mario R Mautino for his help in revising this manuscript.

References

  1. 1.
    Baumann BC, Forte P, Hawley RJ, Rieben R, Schneider MK, Seebach JD (2004) Lack of galactose-alpha-1,3-galactose expression on porcine endothelial cells prevents complement-induced lysis but not direct xenogeneic NK cytotoxicity. J Immunol 172:6460–6467PubMedGoogle Scholar
  2. 2.
    Cui Z, Willingham MC (2004) The effect of aging on cellular immunity against cancer in SR/CR mice. Cancer Immunol Immunother 53:473–478CrossRefPubMedGoogle Scholar
  3. 3.
    Cui Z, Willingham MC et al (2003) Spontaneous regression of advanced cancer: identification of a unique genetically determined, age-dependent trait in mice. Proc Natl Acad Sci USA 100:6682–6687CrossRefPubMedGoogle Scholar
  4. 4.
    Finkelstein SE, Heimann DM et al (2004) Bedside to bench and back again: how animal models are guiding the development of new immunotherapies for cancer. J Leukoc Biol 76:333–337CrossRefPubMedGoogle Scholar
  5. 5.
    Galili U (2004) Autologous tumor vaccines processed to express alpha-gal epitopes: a practical approach to immunotherapy in cancer. Cancer Immunol Immunother 53(11):935–945CrossRefPubMedGoogle Scholar
  6. 6.
    Galili U, Anaraki F, Thall A, Hill-Black C, Radic M (1993) One percent of human circulating B lymphocytes are capable of producing the natural anti-Gal antibody. Blood 82:2485–2493PubMedGoogle Scholar
  7. 7.
    Galili U, LaTemple DC (1997) Natural anti-Gal antibody as a universal augmenter of autologous tumor vaccine immunogenicity. Immunol Today 18:281–285CrossRefPubMedGoogle Scholar
  8. 8.
    Galili U, Mandrell RE, Hamadeh RM, Shohet SB, Griffiss JM (1988) Interaction between human natural anti-alpha-galactosyl immunoglobulin G and bacteria of the human flora. Infect Immun 56:1730–1737PubMedGoogle Scholar
  9. 9.
    Galili U, Shohet SB, Kobrin E, Stults CL, Macher BA (1988) Man, apes, and Old World monkeys differ from other mammals in the expression of alpha-galactosyl epitopes on nucleated cells. J Biol Chem 263:17755–17762PubMedGoogle Scholar
  10. 10.
    Gorelik E, Duty L, Anaraki F, Galili U (1995) Alterations of cell surface carbohydrates and inhibition of metastatic property of murine melanomas by alpha 1,3 galactosyltransferase gene transfection. Cancer Res 55:4168–4173PubMedGoogle Scholar
  11. 11.
    Greiner JW, Zeytin H, Anver MR, Schlom J (2002) Vaccine-based therapy directed against carcinoembryonic antigen demonstrates antitumor activity on spontaneous intestinal tumors in the absence of autoimmunity. Cancer Res 62:6944–6951PubMedGoogle Scholar
  12. 12.
    Gross DA, Graff-Dubois S et al (2004) High vaccination efficiency of low-affinity epitopes in antitumor immunotherapy. J Clin Invest 113:425–433CrossRefPubMedGoogle Scholar
  13. 13.
    Hamadeh RM, Jarvis GA, Galili U, Mandrell RE, Zhou P, Griffiss JM (1992) Human natural anti-Gal IgG regulates alternative complement pathway activation on bacterial surfaces. J Clin Invest 89:1223–1235PubMedGoogle Scholar
  14. 14.
    Hodge JW, Grosenbach DW, Aarts WM, Poole DJ, Schlom J (2003) Vaccine therapy of established tumors in the absence of autoimmunity. Clin Cancer Res 9:1837–1849PubMedGoogle Scholar
  15. 15.
    Induction and measurement of cytotoxic t lymphocyte activity (2001) Current protocols in immunology Chapter 3. In: Coico R (ed) Vitro Assays for Mouse Lymphocyte Function. John Wiley& Sons, New YorkGoogle Scholar
  16. 16.
    Joziasse DH, Oriol R (1999) Xenotransplantation: the importance of the Galalpha1,3Gal epitope in hyperacute vascular rejection. Biochim Biophys Acta 1455:403–418PubMedGoogle Scholar
  17. 17.
    Kawahara T, Ohdan H, Zhao G, Yang YG, Sykes M (2003) Peritoneal cavity B cells are precursors of splenic IgM natural antibody-producing cells. J Immunol 171:5406–5414PubMedGoogle Scholar
  18. 18.
    Kim M, Rao MV, Tweardy DJ, Prakash M, Galili U, Gorelik E (1993) Lectin-induced apoptosis of tumour cells. Glycobiology 3:447–453PubMedGoogle Scholar
  19. 19.
    Larsen RD, Rivera-Marrero CA, Ernst LK, Cummings RD, Lowe JB (1990) Frameshift and nonsense mutations in a human genomic sequence homologous to a murine UDP-Gal:beta-D-Gal(1,4)-D-GlcNAc alpha(1,3)- galactosyltransferase cDNA. J Biol Chem 265:7055–7061PubMedGoogle Scholar
  20. 20.
    LaTemple DC, Abrams JT, Zhang SY, Galili U (1999) Increased immunogenicity of tumor vaccines complexed with anti-Gal: studies in knockout mice for alpha1,3galactosyltransferase. Cancer Res 59:3417–3423PubMedGoogle Scholar
  21. 21.
    LaTemple DC, Galili U (1998) Adult and neonatal anti-Gal response in knock-out mice for alpha1,3galactosyltransferase. Xenotransplantation 5:191–196PubMedGoogle Scholar
  22. 22.
    Leitner WW, Hwang LN, deVeer MJ, Zhou A, Silverman RH, Williams BR, Dubensky TW, Ying H, Restifo NP (2003) Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathways. Nat Med 9:33–39CrossRefPubMedGoogle Scholar
  23. 23.
    Link CJ Jr, Seregina T, Atchison R, Hall A, Muldoon R, Levy JP (1998) Eliciting hyperacute xenograft response to treat human cancer: alpha(1,3) galactosyltransferase gene therapy. Anticancer Res 18:2301–2308PubMedGoogle Scholar
  24. 24.
    Overwijk WW, Lee DS et al (1999) Vaccination with a recombinant vaccinia virus encoding a “self” antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes. Proc Natl Acad Sci USA 96:2982–2987CrossRefPubMedGoogle Scholar
  25. 25.
    Overwijk WW, Theoret MR et al (2003) Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med 198:569–580CrossRefPubMedGoogle Scholar
  26. 26.
    Phan GQ, Yang JC et al (2003) Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA 100:8372–8377CrossRefPubMedGoogle Scholar
  27. 27.
    Posekany KJ, Pittman HK, Bradfield JF, Haisch CE, Verbanac KM (2002) Induction of cytolytic anti-Gal antibodies in alpha-1,3-galactosyltransferase gene knockout mice by oral inoculation with Escherichia coli O86:B7 bacteria. Infect Immun 70:6215–6222CrossRefPubMedGoogle Scholar
  28. 28.
    Posekany KJ, Pittman HK, Swanson MS, Haisch CE, Verbanac KM (2004) Suppression of Lewis lung tumor development in alpha 1,3 galactosyltransferase knock-out mice. Anticancer Res 24:605–612PubMedGoogle Scholar
  29. 29.
    Rosenberg SA (2001) Progress in human tumour immunology and immunotherapy. Nature 411:380–384CrossRefPubMedGoogle Scholar
  30. 30.
    Schaapherder AF, Daha MR, te Bulte MT, van der Woude FJ, Gooszen HG (1994) Antibody-dependent cell-mediated cytotoxicity against porcine endothelium induced by a majority of human sera. Transplantation 57:1376–1382PubMedGoogle Scholar
  31. 31.
    Spiro RG, Bhoyroo VD (1984) Occurrence of alpha-D-galactosyl residues in the thyroglobulins from several species. Localization in the saccharide chains of the complex carbohydrate units. J Biol Chem 259:9858–9866PubMedGoogle Scholar
  32. 32.
    Thall AD, Maly P, Lowe JB (1995) Oocyte Gal alpha 1,3Gal epitopes implicated in sperm adhesion to the zona pellucida glycoprotein ZP3 are not required for fertilization in the mouse. J Biol Chem 270:21437–21440CrossRefPubMedGoogle Scholar
  33. 33.
    Thall AD, Murphy HS, Lowe JB (1996) alpha 1,3-Galactosyltransferase-deficient mice produce naturally occurring cytotoxic anti-Gal antibodies. Transplant Proc 28:556–557PubMedGoogle Scholar
  34. 34.
    Unfer RC, Hellrung D, Link CJ Jr (2003) Immunity to the alpha(1,3)galactosyl epitope provides protection in mice challenged with colon cancer cells expressing alpha(1,3)galactosyl-transferase: a novel suicide gene for cancer gene therapy. Cancer Res 63:987–993PubMedGoogle Scholar
  35. 35.
    van Elsas A, Hurwitz AA, Allison JP (1999) Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med 190:355–366CrossRefPubMedGoogle Scholar
  36. 36.
    van Elsas A, Sutmuller RP et al (2001) Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy. J Exp Med 194:481–489CrossRefPubMedGoogle Scholar
  37. 37.
    Watier H, Guillaumin JM, Piller F, Lacord M, Thibault G, Lebranchu Y, Monsigny M, Bardos P (1996) Removal of terminal alpha-galactosyl residues from xenogeneic porcine endothelial cells. Decrease in complement-mediated cytotoxicity but persistence of IgG1-mediated antibody-dependent cell-mediated cytotoxicity. Transplantation 62:105–113CrossRefPubMedGoogle Scholar
  38. 38.
    Watier H, Guillaumin JM, Vallee I, Thibault G, Gruel Y, Lebranchu Y, Bardos P (1996) Human NK cell-mediated direct and IgG-dependent cytotoxicity against xenogeneic porcine endothelial cells. Transpl Immunol 4:293–299CrossRefPubMedGoogle Scholar
  39. 39.
    Zhu Z, Sanchez-Sweatman O, Huang X, Wiltrout R, Khokha R, Zhao Q, Gorelik E (2001) Anoikis and metastatic potential of cloudman S91 melanoma cells. Cancer Res 61:1707–1716PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2005

Authors and Affiliations

  • Gabriela R. Rossi
    • 1
    • 2
    Email author
  • Robert C. Unfer
    • 2
  • Tatiana Seregina
    • 1
    • 2
  • Charles J. Link
    • 1
    • 2
  1. 1.Tumor Immunology SectionNewLink Genetics CorporationAmes
  2. 2.Iowa Cancer Research FoundationUrbandale

Personalised recommendations